Case study: Adult with uncontrolled type 2 diabetes of 3 years duration
|
|
- Kelly Higgins
- 7 years ago
- Views:
Transcription
1 Case study: Adult with uncontrolled type 2 diabetes of 3 years duration Authored by Pablo Aschner and Linong Ji on behalf of the Global Partnership for Effective Diabetes Management. The Global Partnership for Effective Diabetes Management is supported by an unrestricted educational grant from Bristol-Myers Squibb, AstraZeneca LP.
2 This case study outlines the treatment of an adult who was diagnosed with type 2 diabetes 3 years ago and has uncontrolled hyperglycaemia (HbA 1c 9%; 75 mmol/mol) The case reflects a full range of treatment and management tools available in the European/US context* *The management of any patient is subject to social, economic, gender, age, co-morbidity and ethnic variables, and is dependent on the range of treatment options available in specific regions or countries.
3 Patient history and current medication use John, 56 years old, lives with his wife He works as a used car salesman, which involves long hours John was diagnosed with type 2 diabetes 3 years ago; since then, he has lost 7 kg (15.4 lbs) John s control of his diabetes fluctuates and his blood glucose levels have risen gradually Coinciding with this, he underwent upward titrations of metformin to try to establish glycaemic control 12 months ago John was also prescribed a DPP-4 inhibitor as a result of further serious deteriorations in blood glycaemic control Current medication Metformin 1000 mg b.i.d. Sitagliptin 100 mg o.d. Valsartan 200 mg o.d. b.i.d., twice daily; o.d., once daily.
4 Current status/biochemistry Previous visit (1 month ago) FPG: 13.7 mmol/l HbA 1c : 9.1% LDL-cholesterol: 1.2 mmol/l HDL-cholesterol: 1.6 mmol/l Triglycerides: 1.3 mmol/l Blood pressure: 126/78 mmhg BMI: 27.7 kg/m 2 Current visit FPG: 14.1 mmol/l HbA 1c : 9.3% LDL-cholesterol: 1.1 mmol/l HDL-cholesterol: 1.5 mmol/l Triglycerides: 1.2 mmol/l Blood pressure: 124/77 mmhg BMI: 27.5 kg/m 2 At John s previous visit, his HbA 1c was substantially above his target range of % and has risen further. The doctor reminded John about the importance of sticking rigidly to diet and exercise interventions and taking his medication as prescribed. He also suggested they needed to revise John s therapy. Click here to change units BMI, body mass index; FPG, fasting plasma glucose; HbA 1c, glycosylated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
5 Current status/biochemistry Previous visit (1 month ago) FPG: 247 mg/dl HbA 1c : 76 mmol/mol LDL-cholesterol: 46 mg/dl HDL-cholesterol: 62 mg/dl Triglycerides: 115 mg/dl Blood pressure: 126/78 mmhg BMI: 27.7 kg/m 2 Current visit FPG: 254 mg/dl HbA 1c : 78 mmol/mol LDL-cholesterol: 43 mg/dl HDL-cholesterol: 58 mg/dl Triglycerides: 106 mg/dl Blood pressure: 124/77 mmhg BMI: 27.5 kg/m 2 At John s previous visit, his HbA 1c was substantially above his target range of mmol/mol. The doctor reminded John about the importance of sticking rigidly to diet and exercise interventions and taking his medication as prescribed. He also suggested they needed to revise John s therapy. Click here to change units BMI, body mass index; FPG, fasting plasma glucose; HbA 1c, glycosylated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
6 Response to poor control Question What is an appropriate response to John s lack of glycaemic control? Ask John to return for reassessment in 1 month Explore the reasons for poor glycaemic control Intensify antihyperglycaemic therapy
7 Response to poor control Question What is an appropriate response to John s lack of glycaemic control? Ask John to return for reassessment in 1 month Explore the reasons for poor glycaemic control Intensify antihyperglycaemic therapy John s blood glucose levels are already uncontrolled; this places John at risk of a range of vascular complications As such, extended periods of uncontrolled hyperglycaemia should be avoided 1 Achieving glycaemic control requires careful assessment of the potential reasons for poor disease management 1 If poor adherence is not suspected, medication should be altered without delay in order to provide adequate control 1. Bailey CJ et al. Diab Vasc Dis Res 2013;DOI /
8 Physician-patient discussion The doctor explains the dangers of extended periods of uncontrolled hyperglycaemia. He asks John: If he is adhering to lifestyle interventions and medication To explain his medication regimen Whether he is experiencing any side-effects of therapy If he has any concerns regarding the use of his medication How well he feels he is coping with his diabetes John reports: Good adherence to lifestyle interventions: he tries to be active and eats healthily most of the time That he always takes his medication Mild GI discomfort on occasion, but otherwise no side-effects Generally feels well, and has no major concerns, but is often tired A positive attitude towards his condition GI, gastrointestinal.
9 Glycaemic target Glycaemic targets should always be individualized, based on a range of factors The doctor and John discuss his target for glycaemic control Question What is the most appropriate glycaemic target * for John? <6.0% % % % % % *Equivalent values: 6.0% = 42 mmol/mol; 6.5% = 48 mmol/mol; 7.0% = 53 mmol/mol; 7.5% = 58 mmol/mol; 8.0% = 64 mmol/mol; 8.5% = 69 mmol/mol.
10 Glycaemic target What is the most appropriate glycaemic target * for John? <6.0% % % % % % Long periods of uncontrolled hyperglycaemia increase John s risk of vascular complications A near normal glycaemic target (HbA 1c %) is appropriate for those with inadequate glycaemic control and no complications, if it can be achieved safely and without delay 1 Other factors favouring a more stringent target include John s age and long potential life expectancy, absence of comorbidities and positive attitude 2 A glycaemic target of % is generally reserved for those with newly diagnosed disease and no complications 1,2 *Equivalent values: 6.0% = 42 mmol/mol; 6.5% = 48 mmol/mol; 7.0% = 53 mmol/mol; 7.5% = 58 mmol/mol; 8.0% = 64 mmol/mol; 8.5% = 69 mmol/mol. 1. Bailey CJ et al. Diab Vasc Dis Res 2013;DOI / Inzucchi S E et al. Diabetes Care 2012;35:
11 Achieving glycaemic control The doctor does not feel that poor adherence is the reason for John s lack of glycaemic control He explains to John that his medication requires adjustment in order to restore control of his blood glucose levels He reiterates that continued adherence to diet and exercise interventions is essential if John is to achieve glycaemic control Question Alongside lifestyle interventions, what is an appropriate choice of antihyperglycaemic medication for John? Add a sulphonylurea Add pioglitazone Add basal insulin Add a GLP 1-receptor agonist
12 Option selected: Add a sulphonylurea When glycaemic control is no longer being achieved with dual therapy, progression to triple oral therapy may offer some benefit 1 Sulphonylureas have good glucose lowering efficacy, but are associated with a moderate risk of hypoglycaemia 1,2 Sulphonylureas may also cause weight gain 1,2 In addition, when two oral therapies are no longer providing sufficient control, adding a third oral agent is likely to decrease HbA 1c by 1.5%, which will be insufficient to reach John s glycaemic target 3,4 Sulphonylurea 1,2 HbA 1c efficacy: High Hypoglycaemia risk: Moderate Weight effect: Gain Major side effects: Hypoglycaemia Cost: Low 1. Inzucchi SE et al. Diabetes Care 2012;35: Bailey CJ et al. Diab Vasc Dis Res 2013;DOI / Rosenstock, J et al. Diabetes Care 2006;29: Roberts, VL. Clin Ther 2005;27: Please select another option
13 Option selected: Add pioglitazone When glycaemic control is no longer being achieved with dual therapy, progression to triple oral therapy may offer some benefit 1 Pioglitazone has a low risk of hypoglycaemia; however, it causes weight gain and is associated with an increased risk of fluid retention, heart failure 1,2 and fracture 3 In addition, when two oral therapies are no longer providing sufficient control, adding a third oral agent is likely to decrease HbA 1c by 1.5%, which will be insufficient to reach John s glycaemic target 4,5 Pioglitazone 1,2 HbA 1c efficacy: Intermediate Hypoglycaemia risk: Low Weight effect: Gain Major side effects: Fluid retention Cost: High 1. Inzucchi SE et al. Diabetes Care 2012;35: Bailey CJ et al. Diab Vasc Dis Res 2013;DOI / Dortmuth CR et al. Arch Intern Med 2009;169: Rosenstock, J et al. Diabetes Care;2006;29: Roberts, VL. Clin Ther. 2005;27: Please select another option
14 Option selected: Add a GLP-1 receptor agonist When glycaemic control is no longer being achieved with dual therapy, adding a third non-insulin agent may offer some benefit 1 Advantages of GLP-1 receptor agonists: 1,2 Associated with weight loss Can lower HbA 1c by as much as basal insulin when HbA 1c is <10% 3 However, they are often associated with initial GI discomfort and clinical experience with these agents is currently limited 1,2 GLP-1 agonist 1,2 HbA 1c efficacy: High Hypoglycaemia risk: Low Weight effect: Neutral/loss Major side effects: GI Cost: Moderate GI, gastrointestinal; GLP, glucagon-like protein. 1. Inzucchi SE et al. Diabetes Care 2012;35: Bailey CJ et al. Diab Vasc Dis Res 2013;DOI / Hall, GC et al. Diabet Med 2013;30, Please select another option
15 Option selected: Add basal insulin When glycaemic control is no longer being Insulin achieved with dual therapy, adding a third 1,2 non-insulin agent may offer some benefit 1 HbA 1c efficacy: Highest However, when two oral therapies are no Hypoglycaemia risk: High longer providing sufficient control, the most Weight effect: Gain robust response will usually be with insulin 1,2 Major side effects: Hypoglycaemia Disadvantages of insulin include high risk of hypoglycaemia and weight gain 1,3 Cost: Variable The doctor explains that hypoglycaemic risk can be minimized through SMBG Metformin in combination with insulin may counteract any weight gain and has apparent CV benefits 1,2 By enhancing the residual endogenous insulin response to meals, DPP-4 inhibitors may also confer benefits when used in combination with basal insulin and metformin DPP-4 inhibitors are also weight neutral John is reluctant, but agrees to give this combination a try CV, cardiovascular; DPP, dipeptidyl peptidase; SMBG, self-monitoring of blood glucose. 1. Inzucchi SE et al. Diabetes Care 2012;35: Rosenstock, J et al. Diabetes Care 2006;29: Bailey CJ et al. Diab Vasc Dis Res 2013;DOI /
16 Percentage reduction in event rate Glargine and detemir are long-acting basal insulin analogues; these are often preferred over NPH insulin due to: 1 Longer duration of action (particularly glargine) Less pronounced peak in time-action profiles More consistent effects Decreased risk of hypoglycaemia 2 NPH insulin shows a distinctive peak in time-action profiles, 3 which can increase risk of hypoglycaemia. Risk can be minimized by administering before bedtime The doctor and John decide to use glargine o.d. before bedtime to achieve glycaemic control 2 Choice of insulin Percentage reduction in hypoglycaemic event rates with insulin glargine versus NPH insulin 2 60 Symptomatic events * 50 Confirmed events Severe events 40 * 1. Poon K and King AB. Drug Healthc Patient Saf 2010;2: Mullins P et al. Clin Ther 2007;29: Owens DR et al. Diabetes Care 2000;23: NPH, neutral protamine Hagedorn * * Type 1 diabetes * Type 2 diabetes Data are from 5 (type 1) and 6 (type 2) phase III or IV diabetes trials. Symptomatic = all symptomatic events; confirmed = symptomatic events with a confirmatory glucose level of 3.6 mmol/l (65 mg/dl) or plasma glucose of <3.2 mmol/l (58 mg/dl); severe = symptomatic events requiring treatment assistance from a third party. *p<0.05 compared with NPH insulin.
17 Preventing and managing hypoglycaemia SMBG is an essential component of diabetes management in patients using insulin It is used to adjust medication in response to fluctuations in blood glucose levels, helping to reduce the risk of hypoglycaemic and hyperglycaemic events The doctor advised John to maintain his FPG between 3.9 and 7.2 mmol/l ( mg/dl), 2 and referred him to a specialist diabetes nurse to learn about SMBG, how to adjust insulin dose according to SMBG and how to recognize and respond to hypoglycaemia/hyperglycaemia If John becomes hypoglycaemic and feels able to self treat, he is advised to: Ingest 15 g of glucose or sucrose, wait 15 minutes then take another 15 g glucose/sucrose if BG is <4.0 mmol/l (click i, below, for examples) Have a meal or snack to prevent recurrence once hypoglycaemia is reversed In cases of severe hypoglycaemia, where John requires assistance to treat: 20 g of glucose/sucrose should be given in the first instance to a conscious person 1,2 For an unconscious individual, glucagon may be administered by a friend/caregiver; the emergency services should also be called 1,2 Show examples of 15 g glucose/sucrose 1. Canadian Diabetes Association. Can J Diabetes 2008;32:S20 S American Diabetes Association. Diabetes Care 2013;36:S11 S66. FPG, fasting plasma glucose; SMBG, self-monitoring of blood glucose.
18 Preventing and managing hypoglycaemia SMBG is an essential component of diabetes management in patients using insulin It is used to adjust medication in response to fluctuations in blood glucose levels, helping to reduce the risk of hypoglycaemic and hyperglycaemic events The doctor advised John to maintain his FPG between 3.9 and 7.2 mmol/l ( mg/dl), 2 and referred him to a specialist diabetes nurse to learn about SMBG, how to adjust insulin dose according to SMBG and how to recognize and respond to hypoglycaemia/hyperglycaemia If John becomes hypoglycaemic and feels able to self treat, he is advised to: Ingest 15 g of glucose/sucrose, wait 15 minutes then take another 15 g glucose/sucrose if BG is <4.0 mmol/l (click i, below, for examples) Examples of 15 g of glucose/sucrose for treatment of mild Have a meal or snack to prevent recurrence once hypoglycaemia is reversed to moderate hypoglycaemia In cases of severe hypoglycaemia, where John requires assistance to treat: 2015 g g of of glucose/sucrose in the form should of glucose be given tablets in the first instance to a conscious person 15 ml 1,2 (3 teaspoons) of table sugar dissolved in water For 175 an ml unconscious (3/4 cup) of individual, juice or regular glucagon soft may drink be administered by a friend/caregiver; 15 ml (3 teaspoons) the emergency of honey services should also be called 1,2 Hide examples of 15 g glucose/sucrose 1. Canadian Diabetes Association. Can J Diabetes 2008;32:S20:S American Diabetes Association. Diabetes Care 2013;36:S11 S66. FPG, fasting plasma glucose; SMBG, self-monitoring of blood glucose.
19 3 month follow-up During the past 3 months John has been adjusting his insulin dose (with the help of the nurse) to counteract fluctuations in his blood glucose levels He has responded well to therapy and his HbA 1c is beginning to decrease towards the target level He says self monitoring can sometimes be a bit of a nuisance but nonetheless he maintains good records in his diary John has experienced minimal weight gain (2 kg; 4.4 lbs) The doctor continues to emphasize the importance of adherence to diet and exercise interventions and medication in order to achieve his target blood glucose level Current status FPG: HbA 1c : BP: 7.0 mmol/l (126 mg/dl) 7.5% (58 mmol/mol) 125/78 mmhg BMI: 28.1 kg/m 2 BMI, body mass index; BP, blood pressure; FPG, fasting plasma glucose; HbA 1c, glycosylated haemoglobin.
20 10 Steps to get more type 2 diabetes patients to goal The Global Partnership for Effective Diabetes Management recommends: 1 10 Steps to get more people with type 2 diabetes to goal: Aim for an appropriate individualized glycaemic target, e.g. HbA 1c 6.5 7% (48 53 mmol/mol) (or fasting/preprandial plasma glucose mg/dl [ mmol/l] where assessment of HbA 1c is not possible) when safe and appropriate. Monitor HbA 1c every 3 months in addition to appropriate glucose self-monitoring. Appropriately manage all cardiovascular risk factors. Refer all newly diagnosed patients to a unit specializing in diabetes care where possible. Address the underlying pathophysiology of diabetes, including the treatment of β-cell dysfunction and insulin resistance. Treat to achieve appropriate target HbA 1c within 6 months of diagnosis. After 3 months, if patients are not at the desired target HbA 1c, consider combination therapy. Consider initiating combination therapy or insulin for patients with HbA 1c 9% ( 75 mmol/mol). Use combinations of antihyperglycaemic agents with complementary mechanisms of action. Implement a multidisciplinary team approach that encourages patient self-management, education and self-care, with shared responsibilities to achieve goals. HbA 1c, glycosylated haemoglobin. 1. Bailey CJ et al. Diab Vasc Dis Res 2013;DOI /
21 For more case studies visit International Medical Press. All rights reserved. No responsibility is assumed by the Global Partnership for Effective Diabetes Management or International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Due to rapid advances in the medical sciences, the Global Partnership and International Medical Press recommend that independent verification of diagnoses and drug dosages should be made. Neither the Global Partnership for Effective Diabetes Management or International Medical Press assume liability for any material contained herein.
Case study: Adult who is newly diagnosed with type 2 diabetes and at risk of hypoglycaemia
Case study: Adult who is newly diagnosed with type 2 diabetes and at risk of hypoglycaemia Authored by Lawrence Leiter and Edward Horton on behalf of the Global Partnership for Effective Diabetes Management.
More informationDiabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions
Diabetes Mellitus 1 Chapter 43. Diabetes Mellitus, Self-Assessment Questions 1. A 46-year-old man presents for his annual physical. He states that he has been going to the bathroom more frequently than
More informationINSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
More informationDiabetes: When To Treat With Insulin and Treatment Goals
Diabetes: When To Treat With Insulin and Treatment Goals Lanita. S. White, Pharm.D. Director, UAMS 12 th Street Health and Wellness Center Assistant Professor of Pharmacy Practice, UAMS College of Pharmacy
More informationSHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
More informationWorkshop A Tara Kadis
Workshop A Tara Kadis Considerations/barriers in decision making about insulin verses GLP-1 use in people with type 2 diabetes Which Insulin regimes should we consider? Diabetes is a progressive multi-system
More informationInitiating & titrating insulin & switching in General Practice Workshop 1
Initiating & titrating insulin & switching in General Practice Workshop 1 Workshop goal To make participants comfortable in the timely initiation and titration of insulin Progression of Type 2 Diabetes
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationInsulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust
Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2
More informationType 2 Diabetes: When to Initiate And Intensify Insulin Therapy. Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB
Type 2 Diabetes: When to Initiate And Intensify Insulin Therapy Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB Declarations I have received travel funding and speaker fees
More informationTherapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2
Ministry of Health, Malaysia 2010 First published March 2011 Perkhidmatan Diabetes dan Endokrinologi Kementerian Kesihatan Malaysia Practical guide to Insulin Therapy in Type 2 Diabetes Mellitus Quick
More informationInsulin myths and facts
london medicines evaluation network Insulin myths and facts Statement 1 Insulin is the last resort for patients with Type 2 diabetes After initial metformin and sulfonylurea therapy, NICE and SIGN suggest
More informationInsulin switch & Algorithms Rotorua GP CME June 2011. Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB
Insulin switch & Algorithms Rotorua GP CME June 2011 Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB Goal of workshop Insulin switching make the necessary move Ensure participants are confident with Recognising
More informationThe basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationWhen and how to start insulin: strategies for success in type 2 diabetes
1 When and how to start insulin: strategies for success in type diabetes Treatment of type diabetes in 199: with each step treatment gets more complex Bruce H.R. Wolffenbuttel, MD PhD Professor of Endocrinology
More informationDiabetes and exercise
Diabetes and exercise Summary Symptoms of hypoglycaemia are caused by low blood sugar. Hypoglycaemia can occur if you take your diabetes medication and then do not eat enough or exercise more than usual.
More informationINSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United
More informationA Guide to Monitoring Blood Glucose for Patients with diabetes in Care Homes
A Guide to Monitoring Blood Glucose for Patients with diabetes in Care Homes 1. Summary... 1 2. Background... 2 3. Purpose 2 4. Responsibilities. 2 5. Blood Glucose Monitoring. 2 6. Resident Groups that
More informationA Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or
A Simplified Approach to Initiating Insulin When to Start Insulin: 1. Fasting plasma glucose (FPG) levels >250 mg/dl or 2. Glycated hemoglobin (A1C) >10% or 3. Random plasma glucose consistently >300 mg/dl
More informationCochrane Quality and Productivity topics
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus NICE has developed the Cochrane Quality and Productivity (QP) topics to help the NHS identify practices
More informationINPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco
INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic
More informationType 2 Diabetes. Tabinda Dugal GP Day 4/05/16
Type 2 Diabetes Tabinda Dugal GP Day 4/05/16 Diabetes Diabetes.a growing health crisis in Britain 869m per year 10% of NHS budget Projections.. 5 million by 2025 Youngest patient? T2DM Type 2 diabetes
More informationComparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians
Clinician Research Summary Diabetes Type 2 Diabetes Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians A systematic review of 166 clinical studies published between
More informationInsulin Initiation and Intensification
Insulin Initiation and Intensification ANDREW S. RHINEHART, MD, FACP, CDE MEDICAL DIRECTOR AND DIABETOLOGIST JOHNSTON MEMORIAL DIABETES CARE CENTER Objectives Understand the pharmacodynamics and pharmacokinetics
More informationInsulin use in Type 2 Diabetes. Dr Rick Cutfield. Why? When? How?
Insulin use in Type 2 Diabetes Dr Rick Cutfield Why? When? How? 1 Conflict of Interest I have been on advisory boards or had speaker fees from the following pharmaceutical companies: - Eli Lilly - Novo
More informationEvaluation of: The Local Enhanced Service provision of for Managing Diabetes Injectable Therapies
Evaluation of: The Local Enhanced Service provision of for Managing Diabetes Injectable Therapies Two CCGs have asked the WSYBCSU to evaluate the current Local Enhanced Service (LES) provision in this
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationlinagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd
linagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationAdherence to insulin therapy at a tertiary care diabetes center in South India
Original Article: Adherence to insulin therapy at a tertiary care diabetes center in South India M.S. Raut, J. Balasubramanian, R.M. Anjana, R Unnikrishnan, *V. Mohan Abstract To assess patient adherence
More informationPersonalized Therapy Algorithms for Type 2 Diabetes: A Phenotypization-based Approach
Personalized Therapy Algorithms for Type 2 Diabetes: A Phenotypization-based Approach Riccardo Candido on behalf of the Personalized Therapy AMD Study Group Diabetes Canter A.S.S. 1 Triestina, Italy BACKGROUND
More informationTrends in Prescribing of Drugs for Type 2 Diabetes in General Practice in England (Chart 1) Other intermediate and long-acting insulins
Type 2 Diabetes Type 2 diabetes is the most common form of diabetes, accounting for 90 95% of cases. 1 Charts 1 and 2 reflect the effect of increasing prevalence on prescribing and costs of products used
More informationInitiate Atorvastatin 20mg daily
Type 2 Diabetes Patient Objectives Stopping Smoking BMI > 25 kg m² Control BP to
More informationManaging diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)
Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic
More informationINSULIN INTENSIFICATION: Taking Care to the Next Level
INSULIN INTENSIFICATION: Taking Care to the Next Level By J. Robin Conway M.D., Diabetes Clinic, Smiths Falls, ON www.diabetesclinic.ca Type 2 Diabetes is an increasing problem in our society, due largely
More informationInsulin pen start checklist
Insulin pen start checklist Topic Instruction Date & Initials 1. Cognitive Assessment 2. Insulin Delivery loading appropriate mixing priming shot dialing up dose delivery of insulin 3. Insulin type/action
More informationManaging the risks of commencing insulin therapy for patients with type 2 diabetes
Managing the risks of commencing insulin therapy for patients with type 2 diabetes Laila King June 213 213 The Health Foundation Insulin is a remedy primarily for the wise, and not for the foolish, whether
More informationType 2 Diabetes. Aims and Objectives. What did you consider? Case Study One: Miss S. Which to choose?!?! Modes of Action
Aims and Objectives This session will outline the increasing complexities of diabetes care, and the factors that differentiate the combinations of therapy, allowing individualisation of diabetes treatment.
More informationEfficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics
Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics This trial is conducted in the United States of America (USA). The aim of this clinical
More informationInsulin therapy in various type 1 diabetes patients workshop
Insulin therapy in various type 1 diabetes patients workshop Bruce H.R. Wolffenbuttel, MD PhD Dept of Endocrinology, UMC Groningen website: www.umcg.net & www.gmed.nl Twitter: @bhrw Case no. 1 Male of
More informationLiraglutide for the treatment of type 2 diabetes
DOI: 10.3310/hta15suppl1/09 Health Technology Assessment 2011; Vol. 15: Suppl. 1 77 Liraglutide for the treatment of type 2 diabetes D Shyangdan, 1 * E Cummins, 2 P Royle 1 and N Waugh 1 1 Department of
More informationIntensifying Insulin Therapy
Intensifying Insulin Therapy Rick Hess, PharmD, CDE, BC-ADM Associate Professor Gatton College of Pharmacy, Department of Pharmacy Practice East Tennessee State University Johnson City, Tennessee Learning
More informationBIAsp30 A 1 chieve Tehran 31 July 2015
BIAsp30 A 1 chieve Tehran 31 July 2015 Beginning insulin with biphasic insulin aspart 30: experience from the A 1 chieve study Professor Philip Home Newcastle University Presenter and sponsor duality of
More informationPharmacological Glycaemic Control in Type 2 Diabetes
Pharmacological Glycaemic Control in Type 2 Diabetes Aim(s) and Objective(s) This guideline aims to offer advice on the pharmacological management for those who require measures beyond diet and exercise
More informationWHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES. Living your life as normal as possible
WHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES DEDBT01954 Lilly Deutschland GmbH Werner-Reimers-Straße 2-4 61352 Bad Homburg Living your life as normal as possible www.lilly-pharma.de www.lilly-diabetes.de
More informationInsulin initiation in type 2 diabetes: Experience and insights
Insulin initiation in type 2 diabetes: Experience and insights Joan Everett A diagnosis of type 2 diabetes can be devastating for the individual and their family. Furthermore, many people with diabetes
More informationInsulin-Treated Diabetes. Guidelines for assessment of fitness to work as Cabin Crew
Insulin-Treated Diabetes Guidelines for assessment of fitness to work as Cabin Crew General Considerations As with all medical guidelines it is important that each individual case is assessed on its own
More informationDiabetes Subcommittee of PTAC meeting. held 18 June 2008. (minutes for web publishing)
Diabetes Subcommittee of PTAC meeting held 18 June 2008 (minutes for web publishing) Diabetes Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics
More informationGuidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
More informationTreatment Approaches to Diabetes
Treatment Approaches to Diabetes Dr. Sarah Swofford, MD, MSPH & Marilee Bomar, GCNS, CDE Quick Overview Lifestyle Oral meds Injectables not insulin Insulin Summary 1 Lifestyle & DM Getting to the point
More informationNCT00272090. sanofi-aventis HOE901_3507. insulin glargine
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationTake a moment Confer with your neighbour And try to solve the following word picture puzzle slides.
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word
More informationAre insulin analogs worth their cost in type 2 diabetes?
Keystone, Colorado 2012 Are insulin analogs worth their cost in type 2 diabetes? Dr. Amanda Adler Consultant Physician, Institute of Metabolic Sciences Addenbrooke s Hospital, Cambridge Chair, Technology
More informationGlycaemic Control in Adults with Type 1 Diabetes
Glycaemic Control in Adults with Type 1 Diabetes Aim(s) and objective(s) This document aims to provide guidance on good clinical practice in managing glycaemic control in adult patients with Type 1 Diabetes
More informationOverview and update of modern type 2 Diabetes philosophy and management. Dr Steve Stanaway Consultant Endocrinologist BCU
Overview and update of modern type 2 Diabetes philosophy and management Dr Steve Stanaway Consultant Endocrinologist BCU Diabetes economics 2009: 2.6M adults with DM in UK (90% type 2) 2025: est. > 4M
More informationBritni Hebert, MD PGY-1
Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,
More information2. What Should Advocates Know About Diabetes? O
2. What Should Advocates Know About Diabetes? O ften a school district s failure to properly address the needs of a student with diabetes is due not to bad faith, but to ignorance or a lack of accurate
More informationType 2 diabetes Definition
Type 2 diabetes Definition Type 2 diabetes is a lifelong (chronic) disease in which there are high levels of sugar (glucose) in the blood. Type 2 diabetes is the most common form of diabetes. Causes Diabetes
More informationCASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure
Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common
More informationUser guide Basal-bolus Insulin Dosing Chart: Adult
Contacts and further information Local contact Clinical pharmacy or visiting pharmacy Diabetes education service Director of Medical Services Visiting or local endocrinologist or diabetes physician For
More informationA propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes
original article Diabetes, Obesity and Metabolism 15: 1120 1127, 2013. 2013 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. original article A propensity score matched
More informationPolicy For The Adjustment Of Insulin Dose For Patients With Diabetes By Diabetes Specialist Dietitians And Cystic Fibrosis Dietitians In NHS Grampian
Policy For The Adjustment Of Insulin Dose For Patients With Diabetes By Diabetes Specialist Dietitians And Cystic Fibrosis Dietitians In NHS Grampian Co-ordinators: Advanced Dietitian (Diabetes) Consultation
More informationInsulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types
Insulin Therapy In Type 2 DM Michael Fischer, M.D., M.S. Sources of support NaRCAD is supported by a grant from the Agency for Healthcare Research and Quality My current research projects are funded by
More informationTreatment of Type 2 Diabetes
Improving Patient Care through Evidence Treatment of Type 2 Diabetes This information is based on a comprehensive review of the evidence for best practices in the treatment of type 2 diabetes and is sponsored
More informationCauses, incidence, and risk factors
Causes, incidence, and risk factors Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both. To understand diabetes,
More informationType 2 diabetes is a progressive. status
Type 2 diabetes is a progressive disease: its treatment the current status Associate Professor Jonathan Shaw Why is type 2 diabetes so hard to treat? How to choose the right glucose-lowering g drug? Page
More informationPresented By: Dr. Nadira Husein
Presented By: Dr. Nadira Husein I have no conflict of interest Disclosures I have received honoraria/educational grants from the following: Novo Nordisk, Eli Lilly, sanofi-aventis, Novartis, Astra Zeneca,
More informationDiabetes Medications: Insulin Therapy
Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta
More informationIt s time to TALK Targets A guide to taking control of your type 2 diabetes
It s time to TALK Targets A guide to taking control of your type 2 diabetes The TALK Targets campaign was initiated and fully funded by Novo Nordisk. By supporting you and your healthcare team, TALK Targets
More informationDistinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationGlucose Tolerance Categories. Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationMedicines for Type 2 Diabetes A Review of the Research for Adults
Medicines for Type 2 Diabetes A Review of the Research for Adults Is This Information Right for Me? Yes, if: Your doctor or health care provider has told you that you have type 2 diabetes and have high
More informationType 2 diabetes mellitus
Type 2 diabetes mellitus CLINICAL PRACTICE Management Guidelines for initiating insulin therapy BACKGROUND Insulin is often indicated for patients with suboptimally controlled type 2 diabetes mellitus,
More informationThe first endoscopically-delivered device therapy for obese patients with type 2 diabetes
DIABETES WEIGHT ENDOBARRIER THERAPY The first endoscopically-delivered device therapy for obese patients with type 2 diabetes Restore the metabolic health of your patients with EndoBarrier Therapy. Dual
More informationUsing human insulin in line with the NICE guideline on type 2 diabetes:
Using human insulin in line with the NICE guideline on type 2 diabetes: Inside: Insulin initiation in type 2 diabetes: What should we be doing? Matthew Oldfield Human insulin in clinical practice: A series
More informationStarting Insulin Sooner Than Later
Starting Insulin Sooner Than Later Rotorua GP Insulin Seminar 13 June 2014 Kingsley Nirmalaraj MBBS, FRACP, FACE Consultant Endocrinologist and Physician Tauranga Hospital/ Bay Endocrinology Ltd Declaration
More informationClinical Guideline Diabetes management during surgery (adults)
Clinical Guideline Diabetes management during surgery (adults) Standard 8 of the National Service Framework for Diabetes states that all children, young people and adults with diabetes admitted to hospital,
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval
More informationInsulin: Breaking Barriers Enhancing Therapies. Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net
Insulin: Breaking Barriers Enhancing Therapies Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net Questions To Address Who are candidates for insulin? When do we start insulin? How do the different types of
More informationIntensive Insulin Therapy in Diabetes Management
Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition
More informationInitiating insulin. type 2 diabetes
Initiating insulin in people with type 2 diabetes Due to its progressive nature, many people with type 2 diabetes will eventually require insulin treatment. Insulin initiation is frequently managed in
More informationSummary of the risk management plan (RMP) for Xultophy (insulin degludec / liraglutide)
EMA/467911/2014 Summary of the risk management plan (RMP) for Xultophy (insulin degludec / liraglutide) This is a summary of the risk management plan (RMP) for Xultophy, which details the measures to be
More informationDM Management in Elderly- What are the glucose targets?
DM Management in Elderly- What are the glucose targets? AFSHAN ZAHEDI, BASC, MD, FRCP(C) ENDOCRINOLOGY WOMEN S COLLEGE HOSPITAL ASSISTANT PROFESSOR OF MEDICINE UNIVERSITY OF TORONTO NOVEMBER 2, 2011 Disclosures
More informationType 2 Diabetes - Pros and Cons of Insulin Administration
Do we need alternative routes of insulin administration (inhaled insulin) in Type 2 diabetes? Cons: Suad Efendic Karolinska Institutet, Sweden The Diabetes Management Situation Today Diabetes is a growing
More informationDietfree-Good News for Diabetics
Dietfree-Good News for Diabetics What is Dietfree? Dietfree is concentrated herbs developed Superdragon TCM UK Ltd and Chinese Medical Academy UK. It is made from a range of pure natural concentrated Chinese
More informationCLASS OBJECTIVES. Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies
Insulins CLASS OBJECTIVES Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies INVENTION OF INSULIN 1921 The first stills used to make insulin
More informationDiabetes in Primary Care course MCQ Answers 2016
Diabetes in Primary Care course MCQ Answers 2016 Diagnosis of Diabetes HbA1C should not be used as a diagnostic tool in the following situations: (answer each TRUE or FALSE) 1. Gestational Diabetes TRUE
More informationDiabetes and the Elimination of Sliding Scale Insulin. Date: April 30 th 2013. Presenter: Derek Sanders, D.Ph.
Diabetes and the Elimination of Sliding Scale Insulin Date: April 30 th 2013 Presenter: Derek Sanders, D.Ph. Background Information Epidemiology and Risk Factors Diabetes Its Definition and Its Impact
More informationInsulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.
Diabetes Definition Diabetes is a chronic (lifelong) disease marked by high levels of sugar in the blood. Causes Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused
More informationTYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES
TYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES Non-insulin regimes Basal insulin only (usually with oral agents) Number of injections 1 Regimen complexity Low Basal insulin +1 meal-time rapidacting insulin
More informationDiabetes Management Tube Feeding/Parenteral Nutrition Order Set (Adult)
Review Due Date: 2016 May PATIENT CARE ORDERS Weight (kg) Known Adverse Reactions or Intolerances DRUG No Yes (list) FOOD No Yes (list) LATEX No Yes ***See Suggestions for Management (on reverse)*** ***If
More informationProtein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075
Title: Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075 Investigator: Institution: Gail Gates, PhD, RD/LD Oklahoma State University Date
More informationGlobal Guideline for Type 2 Diabetes
INTERNATIONAL DIABETES FEDERATION, 2005 Clinical Guidelines Task Force Global Guideline for Type 2 Diabetes Chapter 10: Glucose control: insulin therapy Copyright All rights reserved. No part of this publication
More informationONCE ONLY GLUCAGON and Fast Acting Glucose gel (PGD) For nurse administration under Patient Group Direction (Trust wide PGD in place)
ADULT INSULIN PRERIPTION AND BLOOD GLUCOSE MONITORING CHART Ward CONSULTANT DATE OF ADMISSION Please affix Patient s label here Ward Ward.../...year PATIENT NAME....... DATE OF BIRTH... NHS NUMBER.......
More informationType 2 diabetes in adults
Internal Clinical Guidelines Team Final draft : management Clinical Guideline Update (NG28) Methods, evidence and recommendations December 2015 Final draft Commissioned by the National Institute for Health
More informationDiabetes Fundamentals
Diabetes Fundamentals Prevalence of Diabetes in the U.S. Undiagnosed 10.7% of all people 20+ 23.1% of all people 60+ (12.2 million) Slide provided by Roche Diagnostics Sources: ADA, WHO statistics Prevalence
More informationAlgorithms for Glycemic Management of Type 2 Diabetes
KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association
More informationYour blood sugar will be checked on arrival to Endoscopy and monitored whilst you are there.
GASTROSCOPY TABLET CONTROLLED DIABETES (Including injectable medication which is not insulin) MORNING APOINTMENT Take your tablets as normal on the day before the test. On the day of the test: Omit your
More informationSelf-Monitoring Of Blood Glucose (SMBG)
Self-Monitoring Of Blood Glucose (SMBG) Aim(s) and objective(s) It is important is to ensure that people with Diabetes are given the opportunity to self monitor their blood glucose appropriately as an
More informationClinical and cost-effectiveness of continuous subcutaneous insulin infusion therapy in diabetes.
PROTOCOL Clinical and cost-effectiveness of continuous subcutaneous insulin infusion therapy in diabetes. A. This the revised protocol (April 2002) B. Review team Contact for correspondence: Dr Jill Colquitt
More informationBOLUS INSULIN DOSAGES H. Peter Chase, MD and Erin Cobry, BS
CHAPTER 6: BOLUS INSULIN DOSAGES H. Peter Chase, MD and Erin Cobry, BS WHAT IS BOLUS INSULIN? Bolus insulin dosages refer to the quick bursts of insulin given to cover the carbohydrates in meals or snacks
More information